S. Cedres, I. Nunez, M. Longo, et al., “Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non-Small-Cell Lung Cancer (NSCLC),” Clinical Lung Cancer, Vol. 3, No. 12, 2011, pp. 172-179. http://dx.doi.org/10.1016/j.cllc.2011.03.019

has been cited by the following article:

• TITLE: Investigation of Combining Serum Tumor Biomarkers and Clinical Features for Elderly Lung Cancer Diagnosis and Classification

  AUTHORS: Yingxuan Tian, Min Yu, Li Sun, Xiaoping Ren, Weifeng Liang, Wenli Shang, Shufen Huo, Linghua Liu, Yajuan Ren, Hongxia Wen, Zhuo Yang, Shenghong Wei, Cairong Wang

  KEYWORDS: Lung Cancer; Tumor Biomarkers; Diagnostic Models

  JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.2, February 10, 2014

  ABSTRACT: To evaluate the diagnosis model of serum tumor biomarker and several clinical features diagnose and classification for lung cancer, the solid protein chip technology (C-12) was used to detect the biomarkers of SF, CEA, CA242, NSE, CA125, CA19-9 and CA15-3 in serum and several clinical features of tumors and benign disease in elderly lung cancer patients were collected. Set up a discriminating analysis as a function diagnostic model in clinical elderly lung cancer diagnosis and sub-type discrimination. In combination of 2 obvious clinical indicators and 2 serum markers, it is possible to provide a diagnosis tool for lung cancer. With the help of mathematic model, it is promising to reduce the misjudgment risk based on the previous experience and therefore establish a reliable diagnosing function. This model is simple, cost-effective and easy to adapt in practice, and can also be used in screening of large population.